Search Results

This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text. In the section “Eplontersen”, the administration schedule should be written as […]

Welcome to the summer issue of Heart International. We are excited to present a collection of insightful articles that delve into various aspects of cardiovascular health and related interventions. This issue encompasses a wide array of topics, from novel treatment strategies and cutting-edge technologies to critical reviews and original research findings, each contributing to our […]

Infiltrative cardiomyopathies are a diverse group of cardiac diseases caused by the deposition of abnormal substances within the myocardium and include diseases, such as Fabry disease, sarcoidosis and less common genetic diseases, such as Friedreich’s ataxia and Danon disease.1 Cardiac amyloidosis is the exemplar infiltrative cardiomyopathy and is characterized by the deposition of misfolded precursor proteins into […]

The landscape of managing atrial fibrillation (AF), the most common cardiac arrhythmia and leading cause of stroke, has undergone a period of change following the development of various treatment modalities and risk-modifying strategies designed to mitigate the risk of stroke in patients with AF.1,2 In this expert interview, Tony D Grayson and Carol Hughes highlight the role of direct […]

Welcome to the latest issue of Heart International. This edition includes a range of articles on topics showcasing the latest advances in our understanding and treatment of cardiovascular disease. We begin with focus on the hereditary cardiac disorder, hypertrophic cardiomyopathy, which previously had a limited treatment options. However, with the approval of the myosin inhibitor, […]

The systemic amyloidoses are a group of heterogenous diseases, which are characterized by the deposition of insoluble amyloid fibrils within the extracellular matrix of multiple organs throughout the body. Amyloid fibrils are formed from the misfolding of amyloid precursor proteins (APPs) into insoluble, beta-pleated sheets that are resistant to proteolysis. They are histologically characterized by […]

Transthyretin amyloid cardiomyopathy (ATTR-CM) is associated with progressive heart failure and at present, few disease-modifying treatments exist. NNC6019-0001 is a humanized monoclonal antibody designed to deplete amyloid fibrils that result in heart failure. In this touchCARDIO interview, we speak with Professor Marianna Fontana (National Amyloidosis Centre, University College London, Royal Free Campus, London, UK) to […]

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a chronic condition associated with progressive heart failure. In this touchCARDIO interview, we speak with Professor Marianna Fontana (National Amyloidosis Centre, University College London, Royal Free Campus, London, UK) to discuss the pathogenesis, prognosis and the unmet needs in the treatment of ATTR-CM. The abstract entitled ‘NNC60190001, a humanized monoclonal […]